Bradley A. McGregor, MD
The bladder cancer armamentarium gained a powerful agent in December 2019 with the approval of enfortumab vedotin-ejfv (Padcev), a Nectin-4–directed antibody-drug conjugate (ADC). The agency granted accelerated approval to the firstin- class agent for adults with locally advanced or metastatic urothelial cancer who have previously received a PD-1/PD-L1 inhibitor and a platinum-containing chemotherapy in the neoadjuvant, adjuvant, locally advanced, or metastatic setting. The decision was based on the tumor response rate observed in the phase II single-arm EV-201 trial (NCT03219333).
Enfortumab vedotin “is a new standard of care” for patients whose disease progresses after prior immunotherapy and platinum-based therapy, said Bradley McGregor, MD, an investigator of the EV-201 study, in an interview with OncLive®
McGregor, a hematologist/oncologist and the clinical director of the Lank Center for Genitourinary Oncology at the Dana-Farber Cancer Institute in Boston, Massachusetts, discussed enfortumab vedotin-ejfv’s path to approval and its future potential in bladder cancer.
... to read the full story